JP5952737B2 - 哺乳動物由来グリア制限前駆細胞を増大、同定、特徴付けおよび能力増強するための方法および組成物 - Google Patents

哺乳動物由来グリア制限前駆細胞を増大、同定、特徴付けおよび能力増強するための方法および組成物 Download PDF

Info

Publication number
JP5952737B2
JP5952737B2 JP2012538881A JP2012538881A JP5952737B2 JP 5952737 B2 JP5952737 B2 JP 5952737B2 JP 2012538881 A JP2012538881 A JP 2012538881A JP 2012538881 A JP2012538881 A JP 2012538881A JP 5952737 B2 JP5952737 B2 JP 5952737B2
Authority
JP
Japan
Prior art keywords
cells
grp
tissue
positive
mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012538881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510570A5 (enExample
JP2013510570A (ja
Inventor
サンドロック，ロバート
カンパネッリ，ジェームズ，ティー．
エップステイン，デボラ，エー．
Original Assignee
キュー セラピューティックス，インク．
キュー セラピューティックス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュー セラピューティックス，インク．, キュー セラピューティックス，インク． filed Critical キュー セラピューティックス，インク．
Publication of JP2013510570A publication Critical patent/JP2013510570A/ja
Publication of JP2013510570A5 publication Critical patent/JP2013510570A5/ja
Application granted granted Critical
Publication of JP5952737B2 publication Critical patent/JP5952737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
JP2012538881A 2009-11-12 2010-11-09 哺乳動物由来グリア制限前駆細胞を増大、同定、特徴付けおよび能力増強するための方法および組成物 Active JP5952737B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26044109P 2009-11-12 2009-11-12
US61/260,441 2009-11-12
US32679910P 2010-04-22 2010-04-22
US61/326,799 2010-04-22
PCT/US2010/055956 WO2011059952A1 (en) 2009-11-12 2010-11-09 Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016026441A Division JP6346629B2 (ja) 2009-11-12 2016-02-15 哺乳動物由来グリア制限前駆細胞を増大、同定、特徴付けおよび能力増強するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2013510570A JP2013510570A (ja) 2013-03-28
JP2013510570A5 JP2013510570A5 (enExample) 2014-06-19
JP5952737B2 true JP5952737B2 (ja) 2016-07-13

Family

ID=43991980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012538881A Active JP5952737B2 (ja) 2009-11-12 2010-11-09 哺乳動物由来グリア制限前駆細胞を増大、同定、特徴付けおよび能力増強するための方法および組成物
JP2016026441A Active JP6346629B2 (ja) 2009-11-12 2016-02-15 哺乳動物由来グリア制限前駆細胞を増大、同定、特徴付けおよび能力増強するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016026441A Active JP6346629B2 (ja) 2009-11-12 2016-02-15 哺乳動物由来グリア制限前駆細胞を増大、同定、特徴付けおよび能力増強するための方法および組成物

Country Status (11)

Country Link
US (2) US10351823B2 (enExample)
EP (2) EP3269803A3 (enExample)
JP (2) JP5952737B2 (enExample)
CN (2) CN102686721B (enExample)
AU (1) AU2010319680B2 (enExample)
CA (1) CA2780541C (enExample)
DK (1) DK2499238T3 (enExample)
ES (1) ES2649396T3 (enExample)
NO (1) NO2499238T3 (enExample)
PL (1) PL2499238T3 (enExample)
WO (1) WO2011059952A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476376C (en) 2002-02-15 2014-10-21 Cornell Research Foundation, Inc. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
CA2723382A1 (en) 2008-05-08 2009-11-12 University Of Rochester Treating myelin diseases with optimized cell preparations
EP2954046B1 (en) 2013-02-06 2025-10-15 University Of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
CA2959691A1 (en) * 2014-09-26 2016-03-31 The Procter & Gamble Company Products comprising malodor reduction materials
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
CN110913689A (zh) 2017-05-10 2020-03-24 罗切斯特大学 治疗神经精神病症的方法
CN108624560B (zh) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 一种分化培养基及少突胶质前体细胞的制备方法
US10995325B2 (en) 2019-03-21 2021-05-04 Fornia Biosolutions, Inc. Additional phytase variants and methods
KR102322635B1 (ko) * 2021-06-11 2021-11-05 인제대학교 산학협력단 말초신경양 미세조직 제조방법 및 이의 용도
WO2023278783A1 (en) * 2021-06-30 2023-01-05 The Regents Of The University Of California Methods to generate glial restricted neural progenitor cells and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235527B1 (en) * 1997-11-29 2001-05-22 University Of Utah Research Foundation Lineage restricted glial precursors from the central nervous system
CA2295197A1 (en) 1999-09-08 2001-03-08 Appleton Papers Inc. Thermally-responsive record material
US6878543B1 (en) * 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
AR046076A1 (es) * 2003-07-18 2005-11-23 Otsuka Pharma Co Ltd Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida
US20050272149A1 (en) * 2004-06-02 2005-12-08 Life & Brain Gmbh Therapeutic delivery of adenosine into a tissue
WO2009023795A2 (en) * 2007-08-14 2009-02-19 The Johns Hopkins University Cell-based compositions and method for treating conditions of the nervous system

Also Published As

Publication number Publication date
US10351823B2 (en) 2019-07-16
PL2499238T3 (pl) 2018-04-30
AU2010319680B2 (en) 2014-05-29
EP2499238A1 (en) 2012-09-19
WO2011059952A1 (en) 2011-05-19
JP6346629B2 (ja) 2018-06-20
AU2010319680A1 (en) 2012-07-05
NO2499238T3 (enExample) 2018-01-27
US20120230963A1 (en) 2012-09-13
EP2499238B1 (en) 2017-08-30
CN105602889A (zh) 2016-05-25
CN102686721A (zh) 2012-09-19
JP2013510570A (ja) 2013-03-28
CN102686721B (zh) 2016-02-10
ES2649396T3 (es) 2018-01-11
US20190032010A1 (en) 2019-01-31
DK2499238T3 (en) 2017-12-04
EP3269803A3 (en) 2018-04-25
EP3269803A2 (en) 2018-01-17
CA2780541A1 (en) 2011-05-19
JP2016146831A (ja) 2016-08-18
HK1174953A1 (zh) 2013-06-21
CA2780541C (en) 2015-07-14
EP2499238A4 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
JP6346629B2 (ja) 哺乳動物由来グリア制限前駆細胞を増大、同定、特徴付けおよび能力増強するための方法および組成物
Faulkner et al. Human embryonic stem cell-derived oligodendrocyte progenitors for the treatment of spinal cord injury
US6949380B1 (en) Transdifferentiation of epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
TWI586805B (zh) 獲得及維持在體外易於分化為寡樹突細胞－族系細胞之哺乳類神經幹細胞及／或神經祖源細胞的純或增富族群之培養方法
JP4621410B2 (ja) 神経細胞へ分化しうる細胞分画の調製方法及び神経変性疾患治療薬の製造方法
JP4823689B2 (ja) 再ミエリン化および脊髄損傷の治療のためのヒト胚性幹細胞に由来するオリゴデンドロサイト
CN101801396B (zh) 治疗神经变性的方法和组合物
WO2003064601A2 (en) Adult human olfactory stem cell
Sethi et al. Olfactory ensheathing cells promote differentiation of neural stem cells and robust neurite extension
Zujovic et al. Remyelination of the central nervous system: a valuable contribution from the periphery
KR101269125B1 (ko) 노치 신호 활성 유전자를 이용한 줄기세포의 증식 방법
US8748385B2 (en) Adult cerebellum-derived neural stem cells and compositions and methods for producing oligodendrocytes
Vardhan et al. Stem cell engineering approaches for investigating glial cues in central nervous system disorders
JP2018501782A (ja) 運動ニューロン前駆細胞を持続的に成長させる方法及び医薬組成物
HK1174953B (en) Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells
EP2554663A2 (en) Method for obtaining oligodendrocyte precursor cells
Duncan et al. Exogenous cell myelin repair and neuroprotection in multiple sclerosis
WO2005095587A1 (ja) 胚性幹細胞から分化した体性幹細胞の製造方法、及びその用途
Canzi Human stem cells for the treatment of motorneuron diseases: regenerative potential, translatability and development of new biotechnologies. Cellule staminali umane per la cura delle malattie degenerative del motoneurone
Bonner et al. Cellular replacement in spinal cord injury
WO2008124863A1 (en) Method of generating population of cells enriched for undifferentiated cells
HK1093219B (en) Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
HK1190434A (en) Culture method to obtain and maintain a pure or enriched population of mammalian neural stem cells and/or neural progenitor cells that are prone to differentiate into oligodendrocyte-lineage cells in vitro

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160610

R150 Certificate of patent or registration of utility model

Ref document number: 5952737

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250